Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05417126 · ClinicalTrials.gov registry record · Phase 2
Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease
A Phase 2 study, sponsored by Nanoscope Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT05417126: Completed Phase 2 study, sponsored by Nanoscope Therapeutics.
NCT05417126 is a Phase 2 study that has completed, run by Nanoscope Therapeutics. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05417126, a Phase 2 study, has completed, sponsored by Nanoscope Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and effects of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010) in Subjects with Stargardt Disease
Primary Outcome
Type, severity, and incidence of ocular and systemic adverse events (AEs), specifically those related to intravitreal injection of vMCO-010
Interventions
- BIOLOGICAL Gene Therapy-vMCO-010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2023-09-28 |
| Phase | Phase 2 |
What the finished NCT05417126 record still lists
NCT05417126 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Gene Therapy-vMCO-010 is the first listed.
NCT05417126 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05417126 about?
NCT05417126 is a clinical study titled "Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease". The purpose of the study is to evaluate the safety and effects of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010) in Subjects with Stargardt Disease
What is the current status of trial NCT05417126?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2022-07-05. Estimated completion is 2023-09-28.
What interventions are being tested in trial NCT05417126?
The interventions under investigation include: Gene Therapy-vMCO-010 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05417126?
This trial is sponsored by Nanoscope Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05417126's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI